The energetic ingredient in Ozempic and Wegovy might assist scale back the danger of kidney failure in these with Kind 2 diabetes and power kidney illness, in accordance with a examine revealed within the New England Journal of Drugs.
Researchers throughout 28 international locations randomly assigned sufferers with Kind 2 diabetes and power kidney illness to obtain a weekly injection of 1 milligram of semaglutide, the energetic ingredient in Ozempic, or a placebo. Roughly 3,500 sufferers participated within the examine, with half receiving semaglutide and the opposite half a placebo.
The examine, which started in 2019, was funded by Novo Nordisk, which manufactures semaglutide.
In follow-ups amongst individuals, the danger of a kidney illness occasions was discovered to be 24 p.c decrease within the semaglutide group than the placebo group.
“Semaglutide decreased the danger of clinically essential kidney outcomes and loss of life from cardiovascular causes in sufferers with kind 2 diabetes and power kidney illness,” researchers concluded.
Novo Nordisk introduced in October it was halting its trial on kidney outcomes early on account of already assembly “sure pre-specified standards.”
In line with the Nationwide Institute of Diabetes and Digestive and Kidney Illnesses, diabetes is the main explanation for kidney illness, with 1 in 3 diabetics having the situation. About 12 p.c of the U.S. inhabitants is estimated to have diabetes.
Within the U.S., semaglutide is accredited for treating Kind 2 diabetes and weight problems and for lowering the danger of main cardiovascular occasions. The latter is the latest, with federal regulators granting the approval based mostly on the outcomes of a multinational examine additionally funded by Novo Nordisk earlier this 12 months.
Different GLP-1 agonists just like Ozempic are equally being examined to see if they can deal with circumstances apart from diabetes and weight problems. Tirzepatide, offered below the title Mounjaro by Eli Lilly, is presently being studied for any potential advantages in treating power kidney illness in sufferers with weight problems with or with out Kind 2 diabetes.
Earlier research have indicated GLP-1 agonists could possibly assist with different circumstances like habit and lowering the danger of dementia.
